CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Price, Quote, News and Overview
NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock
CYCC Quote and Key Statistics
CYCLACEL PHARMACEUTICALS INC
NASDAQ:CYCC (1/22/2025, 5:35:35 PM)
After market: 0.3501 0 (-0.88%)0.3532
-0.01 (-1.89%)
CYCC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -250.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYCC Performance and Technical Analysis
CYCC Ownership and Analysts
CYCC Latest News and Analysis
These stocks are moving in today's after hours session
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Most active stocks in Friday's session
Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume!
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
About CYCC
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The firm's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Company Info
CYCLACEL PHARMACEUTICALS INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Company Website: https://cyclacel.com/
Investor Relations: http://investor.cyclacel.com/
Phone: 19085177330
CYCC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 299.00B | ||
| AMGN | AMGEN INC | 14.23 | 146.98B | ||
| GILD | GILEAD SCIENCES INC | 21 | 115.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.22 | 110.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 74.73B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.74 | 20.80B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B |